Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

New Partnership Formed to Promote Early Cancer Detection

Washington, D.C. (December 20, 2021) – Today marks the formation of The Cancer Early Detection Alliance (CEDA), a unique collaboration of patient, provider and industry advocates. CEDA is committed to using its collective voice to identify and advance policies that remove barriers to cancer screening, eliminate racial and ethnic disparities in cancer screening, and improve access to innovations in early cancer detection to save lives.

Founding members of CEDA are the American Osteopathic Association (AOA), American Urological Association (AUA), Colon Cancer Coalition, Freenome, Guardant Health, LUNGevity, Ovarian Cancer Research Alliance, Prevent Cancer Foundation, and ZERO – The End of Prostate Cancer.

“The Colon Cancer Coalition is passionate about supporting access to safe and effective cancer screening for all types of cancer. CEDA provides an important opportunity to work with our peers to accomplish this,” states Chris Evans, Colon Cancer Coalition president.

“Improving access to early cancer detection services calls for a ‘big tent.’ CEDA enables us to band together to advance and improve policies that will save lives,” said Jody Hoyos, President & COO of the Prevent Cancer Foundation.

“CEDA’s focus on underserved communities and eliminating racial and ethnic disparities is a critical reason for ZERO’s participation in the alliance,” said Jamie Bearse, CEO of ZERO – The End of Prostate Cancer. “Prostate cancer disproportionately impacts Black men, who are 2.2 times as likely to die of prostate cancer and much more likely to die of low grade disease. This makes early detection among this high risk group, in particular, absolutely vital.”

Initial CEDA priorities will focus on how current mechanisms that influence access and uptake of early cancer screening, such as United States Preventive Services Task Force (USPSTF) recommendations, can be adapted to better reflect patient needs and the rapid pace of research and innovation. As part of this work, CEDA will explore regulatory and legislative opportunities to ensure patients receive timely access to new screening tools once approved for use.

About Cancer Early Detection Alliance (CEDA) 

CEDA consists of national organizations representing a diverse group of stakeholders, including patient advocacy organizations, healthcare professional societies, and industry leaders, all of whom have significant expertise in cancer care and early detection. CEDA’s mission is to promote and expand access to quality, equitable early cancer detection and care, with a specific focus on reaching underserved communities and addressing racial and ethnic disparities.

To join us or for further information on CEDA, visit cedalliance.org.

CONTACT: Peggy Tighe, Peggy.Tighe@powerslaw.com

About ZERO — The End of Prostate Cancer
ZERO — The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer and help all who are impacted. ZERO advances research, provides support, and creates solutions to achieve health equity to meet the most critical needs of our community. From early detection to survivorship, ZERO is the premier resource for prostate cancer patients and their families to access comprehensive support, make meaningful connections, and take action to save lives. Our dedicated national and chapter staff is joined with a growing team of passionate volunteer champions to increase advocacy, awareness, and community engagement to ZERO out prostate cancer. ZERO is recognized with four out of four stars by Charity Navigator and accredited by the Better Business Bureau. ZERO spends more on programs than any other prostate cancer charity, dedicating 85 cents of every dollar to support, education, and research.